The strong Week 52 data and adolescent results significantly de-risk the HS BLA. Traders should focus on the BLA acceptance and PDUFA date decision in late November 2026, which will determine launch timing. Also watch for the IZAR-1 Phase 3 PsA readout expected mid-2026 as the next catalyst. The stock may re-rate on regulatory progress, but FDA review risk remains.
Price Chart
Executive Summary
MoonLake announced Week 52 data from Phase 3 VELA program in hidradenitis suppurativa showing 67.2% HiSCR75 and 33.1% HiSCR100, with favorable safety and no new signals. Interim VELA-TEEN data in adolescents showed 68% HiSCR75 at Week 24. BLA submission for sonelokimab in HS is expected end of September 2026, with PDUFA date allocation by end of November 2026 and a Priority Review request. The data supports a potential best-in-class profile and de-risks the regulatory path.
Key Facts
- 67.2% of patients achieved HiSCR75 at Week 52 (pooled VELA-1/-2, n=396)
- 33.1% achieved HiSCR100 and 26.0% achieved IHS4-100 at Week 52
- HiSQOL mean score difference from baseline of -15.0 points at Week 52
- 46.5% of patients had ≥3-point reduction in worst skin pain NRS at Week 52
- VELA-TEEN: 68% HiSCR75, 86% HiSCR50, 45% HiSCR100 at Week 24 (n=22)
- No new safety signals; low rates of IBD (0.1%), SIB (0.2%), and hepatic events (2.0%) at Week 52
- BLA submission for HS expected end of September 2026; PDUFA date allocation expected end of November 2026
- Priority Review requested based on best-in-class profile and adolescent data
- Cash runway to end of 2027 plus access to up to $400M non-dilutive facility with Hercules Capital
Financial Impact
No financial data reported; pre-revenue clinical-stage biotech with cash runway to end of 2027 and up to $400M non-dilutive facility
Risk Factors
- FDA may not accept BLA or may deny Priority Review, delaying launch to Q3/Q4 2027
- Competition from approved IL-17 inhibitors (secukinumab, bimekizumab) with established market presence
- Commercial execution risk as a small biotech entering a competitive HS market
- Reliance on third-party manufacturing and supply chain for commercial batches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-070362 |
| Document: ea029539901ex99-1.htm | 0001213900-26-070362 |
| Document: ea0295399-8k_moonlake.htm | 0001213900-26-070362 |
| Document: 0001213900-26-070362-index-headers.html | 0001213900-26-070362 |
| Document: 0001213900-26-070362-index.html | 0001213900-26-070362 |
| Document: 0001213900-26-070362.txt | 0001213900-26-070362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $17.23 | awaiting T+60 | — | $11.85 (−31.22%) |
Aug 10, 2026 11w ago | 8-K | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Aug 10, 2026 11w ago | Press Release | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Jul 20, 2026 14w ago | Insider Cluster | $19.05 $10.41 | ▲ +45.35% | ▲ +50.19% | $11.85 (+37.80%) |
Jun 25, 2026 17w ago | 8-K | $19.99 $12.39 | ▲ +38.02% | ▲ +41.87% | $11.85 (+40.72%) |
Jun 23, 2026 17w ago | Press Release | $20.00 $12.20 | ▲ +39.00% | ▲ +42.29% | $11.85 (+40.75%) |
Jun 22, 2026 18w ago | 8-K | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 21, 2026 18w ago | Press Release | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $17.75 $15.01 | ▲ +15.44% | ▲ +19.83% | $11.85 (+33.24%) |
Jun 1, 2026 21w ago | 8-K | $18.82 $15.56 | ▼ −17.32% | ▼ −18.55% | $11.85 (−37.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers